About the Company
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HARP News
Merck completes acquisition of Harpoon Therapeutics
Merck (MSD) has concluded the acquisition of all the outstanding shares of US-based Harpoon Therapeutics to broaden its ...
Harpoon Hit With Investor Lawsuit for $680 Million Sale to Merck
An investor sued Harpoon Therapeutics Inc. on Thursday over fears that its planned $680 million sale to Merck & Co. may be aimed at handing a windfall to insiders who were given cheap equity before ...
Merck closes $650M Harpoon acquisition
The transaction brings on additional assets to expand the Rahway-based biopharmaceutical's immuno-oncology research and pipeline.
Harpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Shares of Harpoon Therapeutics, Inc.(NASDAQ: HARP) rose sharply in pre-market trading. Bloomberg reported that Merck is in advanced talks to buy Harpoon Therapeutics for $23 per share. Harpoon ...
New Suit - Securities
Harpoon Therapeutics and its corporate directors were hit with a securities lawsuit on Feb. 13 in Delaware District Court in connection with a proposed acquisition by Merck Sharp & Dohme.
Harpoon Therapeutics Inc HARP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
Stay well-informed and make prudent decisions using our Ratings Table. Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell ...
Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts
Merck (MRK) announced the completion of the acquisition of Harpoon Therapeutics, Inc. (HARP). Harpoon is now a wholly-owned ...
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned ...
Harpoon Therapeutics Inc HARP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Merck concludes acquisition of Harpoon Therapeutics
Rahway: Merck, known as MSD outside of the United States and Canada, has completed the acquisition of Harpoon Therapeutics, ...
Loading the latest forecasts...